Short Interest in OS Therapies Incorporated (NYSEAMERICAN:OSTX) Decreases By 16.7%

OS Therapies Incorporated (NYSEAMERICAN:OSTX) saw a large decline in short interest in March. As of March 13th, there was short interest totaling 1,293,690 shares, a decline of 16.7% from the February 26th total of 1,552,122 shares. Based on an average daily trading volume, of 676,545 shares, the short-interest ratio is currently 1.9 days. Currently, 4.1% of the shares of the stock are short sold.

Analyst Ratings Changes

Separately, D. Boral Capital reaffirmed a “buy” rating and issued a $20.00 price objective on shares of OS Therapies in a research note on Friday. Two analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $18.50.

OS Therapies Price Performance

Shares of NYSEAMERICAN:OSTX opened at $1.41 on Monday. OS Therapies has a one year low of $1.12 and a one year high of $2.57. The company has a market cap of $49.65 million, a price-to-earnings ratio of -1.72 and a beta of -3.80. The firm has a 50 day simple moving average of $1.40 and a 200 day simple moving average of $1.67.

Institutional Investors Weigh In On OS Therapies

Several hedge funds have recently modified their holdings of the company. Susquehanna International Group LLP bought a new stake in OS Therapies during the 3rd quarter worth $29,000. Mercer Global Advisors Inc. ADV bought a new position in OS Therapies in the third quarter valued at about $40,000. Ground Swell Capital LLC acquired a new stake in shares of OS Therapies during the third quarter valued at about $40,000. Bridgeway Capital Management LLC bought a new stake in shares of OS Therapies during the second quarter worth about $47,000. Finally, Jane Street Group LLC bought a new stake in shares of OS Therapies during the fourth quarter worth about $39,000.

OS Therapies Company Profile

OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. OS Therapies Incorporated was incorporated in 2018 and is based in Rockville, Maryland.